A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc, finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co. The two companies have been embroiled in a case involving accusations that Yescarta, the CAR-T cell […]
>> CLICK HERE << Get A FREE Copy Of My Special Report
“Can Your Retirement Survive” Today!
We Even Pay For Shipping & Handling!
|Click Here To Request Your FREE IRS Loophole Guide|
This post contains affiliate links. If you use these links to buy something we may earn a commission. Thanks.”